Feedback informs FDA's reform of user fees crucial for regulatory processes, highlighting program uncertainties.
The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain critical for supporting regulatory operations, but the program's future is unclear.
No takes yet. Share an insight, caveat, or question.
Ziaks et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: